

Jadwiga A Wedzicha

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2223150/jadwiga-a-wedzicha-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

15,896
citations

60
h-index

125
g-index

188
ext. papers

19,146
ext. citations

10.6
avg, IF

6.66
L-index

#	Paper	IF	Citations
164	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38	59.2	1840
163	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 557-582	10.2	1682
162	COPD exacerbations: defining their cause and prevention. <i>Lancet, The</i> , 2007 , 370, 786-96	40	668
161	The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 19-26	10.2	636
160	Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. <i>New England Journal of Medicine</i> , 2016 , 374, 2222-34	59.2	537
159	Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 1298-303	10.2	470
158	Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. <i>Lancet Respiratory Medicine, the</i> , 2013 , 1, 199-209	35.1	385
157	Airway and systemic inflammation and decline in lung function in patients with COPD. <i>Chest</i> , 2005 , 128, 1995-2004	5.3	336
156	Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 867-74	10.2	329
155	Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 1139-47	10.2	314
154	Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 400-7	10.2	314
153	Minimal clinically important differences in pharmacological trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 250-5	10.2	287
152	Increased risk of myocardial infarction and stroke following exacerbation of COPD. <i>Chest</i> , 2010 , 137, 1091-7	5.3	275
151	Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003 , 167, 1090-5	10.2	274
150	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 523-5	10.2	273
149	Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 71-8	10.2	261
148	Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2177-2186	27.4	254

147	Blood eosinophils and inhaled corticosteroid/long-acting β_2 agonist efficacy in COPD. <i>Thorax</i> , 2016 , 71, 118-25	7.3	246
146	Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. <i>Chest</i> , 2006 , 129, 317-324	5.3	233
145	Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 446-52	10.2	220
144	Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. <i>Chest</i> , 2015 , 147, 999-1007	5.3	204
143	Temporal clustering of exacerbations in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 369-74	10.2	187
142	Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 1189-95	10.2	180
141	Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. <i>BMC Medicine</i> , 2013 , 11, 181	11.4	167
140	Exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Care</i> , 2003 , 48, 1204-13; discussion 1213-5	2.1	165
139	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 619-626	35.1	148
138	Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. <i>Thorax</i> , 2012 , 67, 1075-80	7.3	144
137	Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1218-24	10.2	144
136	Outdoor air pollution and respiratory health in patients with COPD. <i>Thorax</i> , 2011 , 66, 591-6	7.3	141
135	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 329-339	10.2	141
134	Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 871-6	10.2	139
133	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27	10.2	137
132	Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2019 , 381, 1257-1266	59.2	136
131	Reported pneumonia in patients with COPD: findings from the INSPIRE study. <i>Chest</i> , 2011 , 139, 505-512	5.3	130
130	Exacerbation rate, health status and mortality in COPD--a review of potential interventions. <i>International Journal of COPD</i> , 2009 , 4, 203-23	3	126

129	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , 2020 , 383, 35-48	59.2	121
128	Human rhinovirus infection during naturally occurring COPD exacerbations. <i>European Respiratory Journal</i> , 2014 , 44, 87-96	13.6	118
127	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1189-1197	10.2	117
126	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 337-344	35.1	116
125	IL-1 β /IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. <i>PLoS ONE</i> , 2011 , 6, e28457	3.7	113
124	Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1091-9	10.2	107
123	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, e56-e69	10.2	104
122	Time course and pattern of COPD exacerbation onset. <i>Thorax</i> , 2012 , 67, 238-43	7.3	100
121	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1540-1551	10.2	94
120	Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. <i>Chest</i> , 2005 , 127, 1219-26	5.3	90
119	Roflumilast: a review of its use in the treatment of COPD. <i>International Journal of COPD</i> , 2016 , 11, 81-90		89
118	Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. <i>Chest</i> , 2010 , 137, 812-22	5.3	88
117	The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 662-72	10.2	85
116	Acute COPD exacerbations. <i>Clinics in Chest Medicine</i> , 2014 , 35, 157-63	5.3	85
115	Efficacy of roflumilast in the COPD frequent exacerbator phenotype. <i>Chest</i> , 2013 , 143, 1302-1311	5.3	84
114	Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 943-50	10.2	82
113	The role of bronchodilator treatment in the prevention of exacerbations of COPD. <i>European Respiratory Journal</i> , 2012 , 40, 1545-54	13.6	82
112	The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. <i>Chest</i> , 2012 , 141, 851-857	5.3	69

111	Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, S63-70	3.4	68
110	A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. <i>Value in Health</i> , 2004 , 7, 153-67	3.3	68
109	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPD MAP study. <i>Thorax</i> , 2018 , 73, 331-338	7.3	67
108	Influence of season on exacerbation characteristics in patients with COPD. <i>Chest</i> , 2012 , 141, 94-100	5.3	67
107	The causes and consequences of seasonal variation in COPD exacerbations. <i>International Journal of COPD</i> , 2014 , 9, 1101-10	3	66
106	Exacerbations: etiology and pathophysiologic mechanisms. <i>Chest</i> , 2002 , 121, 136S-141S	5.3	64
105	Combined Impact of Smoking and Early-Life Exposures on Adult Lung Function Trajectories. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1021-1030	10.2	61
104	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 139-149	10.2	54
103	Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). <i>European Respiratory Journal</i> , 2014 , 43, 735-44	13.6	51
102	Controversies in treatment of chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2011 , 378, 1038-47	4.0	51
101	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 541-9	10.2	47
100	Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013 , 14, 79	7.3	47
99	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015 , 70, 930-8	7.3	45
98	Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. <i>Clinics in Chest Medicine</i> , 2020 , 41, 421-438	5.3	45
97	Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016 , 48, 880-8	13.6	44
96	Research Priorities in Pathophysiology for Sleep-disordered Breathing in Patients with Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 289-299	10.2	42
95	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. <i>PLoS ONE</i> , 2016 , 11, e0163139	3.7	41
94	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 739-750	10.2	40

93	Physical activity and exercise capacity in patients with moderate COPD exacerbations. <i>European Respiratory Journal</i> , 2016 , 48, 340-9	13.6	40
92	Viral infections in obstructive airway diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2003 , 9, 111-6	3	39
91	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 553-564	10.2	38
90	Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2014 , 9, 1241-52	3	28
89	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 17-22	10.2	27
88	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 414-423	10.2	26
87	Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. <i>International Journal of COPD</i> , 2017 , 12, 339-349	3	25
86	The biology of a chronic obstructive pulmonary disease exacerbation. <i>Clinics in Chest Medicine</i> , 2007 , 28, 525-36, v	5.3	25
85	Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2014 , 24, 14015	3.2	23
84	Triple Therapy in COPD: What We Know and What We Don't. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017 , 14, 648-662	2	23
83	Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007 , 4, 177-83	2	22
82	Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. <i>Clinical Physiology and Functional Imaging</i> , 2006 , 26, 251-6	2.4	22
81	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , 2013 , 41, 12-7	13.6	21
80	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1488-1502	10.2	21
79	Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1496-1507	10.2	21
78	Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 937-8	10.2	20
77	A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1254-1267	10.2	19
76	Editorial Changes and Opportunities at theAJRCCM. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1-2	10.2	19

75	Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 166-184	2.7	19
74	The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 267-75	3.9	18
73	Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. <i>European Respiratory Journal</i> , 2012 , 40, 1123-9	13.6	18
72	Increased Chronic Obstructive Pulmonary Disease Exacerbations of Likely Viral Etiology Follow Elevated Ambient Nitrogen Oxides. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 581-591	10.2	18
71	Predicting In-Hospital Treatment Failure (≥ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 82-92	2	17
70	Sputum-to-serum hydrogen sulfide ratio in COPD. <i>Thorax</i> , 2014 , 69, 903-9	7.3	17
69	Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2013 , 22, 271-7		17
68	Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1223-1226	10.2	17
67	The Effects of a Video Intervention on Posthospitalization Pulmonary Rehabilitation Uptake. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 1517-1524	10.2	16
66	Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2007 , 4, 602-5		16
65	Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 730-738	10.2	15
64	Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations. <i>Annals of the American Thoracic Society</i> , 2015 , 12 Suppl 2, S157-9	4.7	14
63	Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation in vivo and in vitro. <i>European Respiratory Journal</i> , 2012 , 40, 1180-90	13.6	14
62	Can patients with COPD self-manage?. <i>Lancet, The</i> , 2012 , 380, 624-5	4.0	13
61	Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010 , 19, 260-5		13
60	Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. <i>International Journal of COPD</i> , 2019 , 14, 2733-2744	3	13
59	Choice of bronchodilator therapy for patients with COPD. <i>New England Journal of Medicine</i> , 2011 , 364, 1167-8	59.2	11
58	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , 2021 , 26, 532-551	3.6	11

57	Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 656-659	10.2	10
56	Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 997-1004	4.7	10
55	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 1251-1258	10.2	10
54	Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. <i>Respirology</i> , 2020 , 25, 393-400	3.6	9
53	Prediction of Chronic Obstructive Pulmonary Disease Exacerbation Frequency. Clinical Parameters Are Still Better Than Biomarkers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 415-416	10.2	8
52	Update in Chronic Obstructive Pulmonary Disease 2016. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 414-424	10.2	8
51	COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. <i>Thorax</i> , 2020 , 75, 351-353	7.3	8
50	Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 400-403	10.2	8
49	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018 , 13, 1125-1134	3	8
48	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014 , 307, L311-6 ^{5.8}	5.8	8
47	Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 669-676	2	8
46	AJRCCM 2017: 100-Year Anniversary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1	10.2	7
45	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	7
44	Update in Chronic Obstructive Pulmonary Disease 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1036-44	10.2	6
43	GOLD and ABCD--a good start, but now for the evidence?. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 4-5	35.1	6
42	Dual PDE 3/4 inhibition: a novel approach to airway disease?. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 669-70	35.1	5
41	Community-based recruitment of patients with COPD into clinical research. <i>Thorax</i> , 2014 , 69, 951-2	7.3	5
40	BODE plus DOSE plus PaO ₂ equals DO RE MI BOX?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 1089-1089	10.2	5

39	The Effect of Acclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 642-645	10.2	4
38	Indacaterol-Glycopyrronium for COPD. <i>New England Journal of Medicine</i> , 2016 , 375, 899-900	59.2	4
37	Antibiotics at COPD exacerbations: the debate continues. <i>Thorax</i> , 2008 , 63, 940-2	7.3	4
36	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials. <i>Advances in Therapy</i> , 2020 , 37, 4266-4279	4.1	4
35	Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. <i>Respiratory Research</i> , 2020 , 21, 93	7.3	4
34	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO Trials. <i>Advances in Therapy</i> , 2021 , 38, 579-593	4.1	4
33	Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 527-8	10.2	3
32	MUC5AC drives COPD exacerbation severity through amplification of virus-induced airway inflammation		3
31	Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 549-557	10.2	3
30	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.. <i>International Journal of COPD</i> , 2022 , 17, 545-558	3	3
29	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 43-51	10.2	2
28	Dual Bronchodilation With Once-Daily QVA149 Reduces Exacerbations, Improves Lung Function and Health Status Versus Glycopyrronium and Tiotropium in Severe-to-Very Severe COPD Patients: The SPARK Study. <i>Chest</i> , 2014 , 145, 406A	5.3	2
27	Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study. <i>Chest</i> , 2014 , 145, 427A	5.3	2
26	A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study. <i>Chest</i> , 2014 , 145, 408A	5.3	2
25	Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1230-1231	10.2	2
24	Outcome of long-term noninvasive positive-pressure ventilation. <i>Respiratory Care Clinics of North America</i> , 2002 , 8, 559-73		2
23	Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients. <i>International Journal of COPD</i> , 2020 , 15, 1831-1838	3	2
22	Response. <i>Chest</i> , 2014 , 145, 428	5.3	1

21	NICE and GOLD response. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 442	35.1	1
20	QVA149 versus glycopyrronium for COPD - authors' reply. <i>Lancet Respiratory Medicine</i> , 2013 , 1, e23	35.1	1
19	ERS publications: the flagship and the fleet. <i>European Respiratory Journal</i> , 2012 , 40, 535-537	13.6	1
18	Integrating Home-Based Exercise Training with a Hospital at Home Service for Patients Hospitalised with Acute Exacerbations of COPD: Developing the Model Using Accelerated Experience-Based Co-Design. <i>International Journal of COPD</i> , 2021 , 16, 1035-1049	3	1
17	Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 1075-1085	10.2	1
16	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 390-392	10.2	1
15	Is Peer Review Still Anonymous?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 278-280	10.2	0
14	Childhood Exposures, Asthma, Smoking, Interactions, and the Catch-Up Hypothesis. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1241-1242	4.7	0
13	AJRCCM: 100-Year Anniversary. The Long View and the Fast Lane. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1081-1085	10.2	
12	Reply to Janaudis-Ferreira : One Step at a Time: A Phased Approach to Behavioral Treatment Development in Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 775-777	10.2	
11	Thorax 2010: celebrating the success of an international respiratory journal. <i>Thorax</i> , 2010 , 65, 755-756	7.3	
10	Prescribing home oxygen therapy for chronic respiratory conditions. <i>The Prescriber</i> , 2009 , 20, 34-37	0.4	
9	Treating COPD exacerbations 2012 , 26-39		
8	The INSPIRE Trial Results: Are They Truly Breathtaking?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 80-81	10.2	
7	Temporal Clustering of COPD Exacerbations May Reflect Corticosteroid Withdrawal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 483-483	10.2	
6	Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 106-107	10.2	
5	The INSPIRE Study: Influence of Prior Use and Discontinuation of Inhaled Corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 544-544	10.2	
4	Early Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 292-292	10.2	

- 3 Fatal cardiovascular complication 19 years after treatment for fibrosarcoma. *British Journal of Hospital Medicine*, **1999**, 60, 604-5
- 2 Reply to Thomson, to Neder ., and to Wouters. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 112 10.2
- 1 Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 968-969 10.2